ADVERTISEMENT
Combo Therapy Regimen a Potential New Standard for Recurrent Ovarian Cancer
Carboplatin plus pegylated liposomal doxorubicin and bevacizumab has been posited as a new standard treatment option for patients with recurrent ovarian cancer, according to results from a phase 3 clinical trial (Lancet Oncol. 2020 May 2. Epub ahead of print).
“State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin–paclitaxel or carboplatin–gemcitabine) or the most active non-bevacizumab regimen: carboplatin–pegylated liposomal doxorubicin,” explained Jacobus Pfisterer, MD, Gynaecologic Oncology Center, Kiel, Germany, and colleagues.
In the multi-center study, Dr Pfisterer et al sought to compare a standard bevacizumab-containing regimen with carboplatin plus pegylated liposomal doxorubicin and bevacizumab in 682 patients.
These patients were enrolled in the study between August 2013 and July 2015 and randomized to receive standard carboplatin plus gemcitabine and bevacizumab (standard arm; n = 337) or carboplatin plus pegylated liposomal doxorubicin and bevacizumab (experimental arm; n = 345).
The primary end point was progression-free survival (PFS).
Ultimately, the median follow-up time frame was 11.3 months in the standard arm versus 12.4 in the experimental arm, and the median PFS was 11.6 months versus 13.3 months, respectively (hazard ratio, 0.8; 95% CI, 0.68-0.95).
Hypertension and neutropenia were the most frequently documented grade 3 or 4 adverse events, and only 1 treatment-related death occurred in the experimental arm.
“Carboplatin-pegylated liposomal doxorubicin-bevacizumab is a new standard treatment option for platinum-eligible recurrent ovarian cancer,” concluded Dr Pfisterer and colleagues.—Kaitlyn Manasterski
